Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial

John Bartlett

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial'. Together they form a unique fingerprint.